One patient with CSF GAD65 antibodies (titer, 3.01 nmol/L; normal, ≤0.02 nmol/L) had mixed vascular cognitive impairment and symptomatic Alzheimer disease (CSF biomarker confirmed). The gene discussed is GAD2; the disease is early-onset autosomal dominant Alzheimer disease.